Medium impact
Besponsa™ (inotuzumab ozogamicin)
Humana·Effective Jan 1, 2026
Humana Louisiana Medicaid has implemented a new prior authorization policy for Besponsa (inotuzumab ozogamicin) effective January 1, 2026. The policy requires prior authorization for this CD22-directed antibody-drug conjugate used to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia in patients 1 year and older. Coverage is limited to monotherapy with approval for up to 6 cycles per authorization period, and claims will be denied if members have experienced disease progression while on or following Besponsa treatment.